source
- FDA issues warning letters to drug makers over CGMP lapses and highlights patient rep ties to industry-backed groupsThe FDA has issued warning letters to several drug manufacturers for failing to meet current good manufacturing practice requirements, citing problems with ensuring product sterility and meeting sp…
- Novartis ends mid-stage Fabhalta trial in lupus nephritis citing strategic considerationsNovartis has terminated its mid-stage trial of Fabhalta (iptacopan) in patients with lupus nephritis, according to a federal clinical trials registry. The company said the decision was driven by s…